Portfolio

SAPPIENS

Drug candidate for Parkinson's disease

Seed round in progress: 4M

Année :

2026

Gabrielle Gache

Licensing specialist, President of the Swiss Healthcare Licensing Group, based at Biopole Lausanne

Pourquoi Valeureux a investi ?

Potentially the first neuroprotective treatment for Parkinson's disease. An open pipeline that includes ALS (Charcot's disease)

Co-investisseurs

By clicking on “Accept all cookies”, you agree that cookies may be stored on your device in order to improve site navigation, analyze site usage, and help us with our marketing efforts.